PloS one, 2015-12, Vol.10 (12), p.e0143190-e0143190
2015
Volltextzugriff (PDF)
Details
- Autor(en) / Beteiligte
- Titel
- Di-(2-Ethylhexyl)-Phthalate (DEHP) Causes Impaired Adipocyte Function and Alters Serum Metabolites
- Ist Teil von
- PloS one, 2015-12, Vol.10 (12), p.e0143190-e0143190
- Ort / Verlag
- United States: Public Library of Science
- Erscheinungsjahr
- 2015
- Quelle
- MEDLINE
- Beschreibungen/Notizen
- Di-(2-ethylhexyl)-phthalate (DEHP), an ubiquitous environmental contaminant, has been shown to cause adverse effects on glucose homeostasis and insulin sensitivity in epidemiological studies, but the underlying mechanisms are still unknown. We therefore tested the hypothesis that chronic DEHP exposure causes impaired insulin sensitivity, affects body weight, adipose tissue (AT) function and circulating metabolic parameters of obesity resistant 129S6 mice in vivo. An obesity-resistant mouse model was chosen to reduce a potential obesity bias of DEHP effects on metabolic parameters and AT function. The metabolic effects of 10-weeks exposure to DEHP were tested by insulin tolerance tests and quantitative assessment of 183 metabolites in mice. Furthermore, 3T3-L1 cells were cultured with DEHP for two days, differentiated into mature adipocytes in which the effects on insulin stimulated glucose and palmitate uptake, lipid content as well as on mRNA/protein expression of key adipocyte genes were investigated. We observed in female mice that DEHP treatment causes enhanced weight gain, fat mass, impaired insulin tolerance, changes in circulating adiponectin and adipose tissue Pparg, adiponectin and estrogen expression. Serum metabolomics indicated a general increase in phospholipid and carnitine concentrations. In vitro, DEHP treatment increases the proliferation rate and alters glucose uptake in adipocytes. Taken together, DEHP has significant effects on adipose tissue (AT) function and alters specific serum metabolites. Although, DEHP treatment led to significantly impaired insulin tolerance, it did not affect glucose tolerance, HOMA-IR, fasting glucose, insulin or triglyceride serum concentrations. This may suggest that DEHP treatment does not cause impaired glucose metabolism at the whole body level.
- Sprache
- Englisch
- Identifikatoren
- ISSN: 1932-6203eISSN: 1932-6203DOI: 10.1371/journal.pone.0143190Titel-ID: cdi_plos_journals_1738753488
- Format
- –
- Schlagworte
- 3T3-L1 Cells, Adipocytes, Adipocytes - drug effects, Adipocytes - metabolism, Adiponectin, Adipose tissue, Adipose Tissue - cytology, Adipose Tissue - drug effects, Adipose Tissue - metabolism, Animals, Biological Transport - drug effects, Blood - drug effects, Blood - metabolism, Body fat, Body weight, Body Weight - drug effects, Body weight gain, Carnitine, Cell Differentiation - drug effects, Cell growth, Cell Proliferation - drug effects, Chemicals, Contaminants, Diabetes, Diethylhexyl Phthalate - metabolism, Diethylhexyl Phthalate - toxicity, Environmental Pollutants - metabolism, Environmental Pollutants - toxicity, Epidemiology, Estrogens, Exposure, Female, Food, Gene expression, Gene Expression Regulation - drug effects, Glucose, Glucose - metabolism, Glucose tolerance, Homeostasis, In vivo methods and tests, Insulin, Insulin Resistance, Laboratory animals, Lipid Metabolism - drug effects, Male, Medicine, Metabolism, Metabolites, Metabolomics, Mice, mRNA, Obesity, Oxidation-Reduction, Palmitic acid, Peroxisome proliferator-activated receptors, Phospholipids, Rodents, Sensitivity, Toxicology